Dosierung und Toxizität von Antirheumatika bei Niereninsuffizienz

Hill AJ, Thomson RJ, Hunter JA et al (2009) The prevalence of chronic kidney disease in rheumatology outpatients. Scott Med J 54:9–12 Karie S, Gandjbakhch F, Janus N et al (2008) Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 47:350–354 Taber SS, Pasko DA (2008) The epidemiology of drug-induced disorders: the kidney. Expert Opin Drug Saf 7:679–690 Lapi F, Azoulay L, Yin H et al (2013) Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case control study. BMJ 346:e8525 Kristensen SL, Fosbøl EL, Kamper AL et al (2012) Use of nonsteroidal anti-inflammatory drugs prior to chronic renal replacement therapy initiation: a nationwide study. Pharmacoepidemiol Drug Saf 21:428–434 Loewen PS (2002) Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. CJEM 4:268–275 Harris RC (2006) COX-2 and the kidney. J Cardiovasc Pharmacol 47(Suppl 1):S37–S42 Agrawal NG, Matthews CZ, Mazenko RS et al (2004) Pharmacokinetics of etoricoxib in patients with renal impairment. J Clin Pharmacol 44:48–58 Chiowchanwisawakit P, Srinonprasert V, Nilganuwong S et al (2012) Antimalarial-induced maculopathy: accuracy of Amsler grid as a diagnostic tool and risk factors. J Med Assoc Thai 95(Suppl 2):S218–S226 Bressolle F, Bologna C, Kinowski JM et al (1998) Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 57:110–113 Beaman JM, Hackett LP, Luxton G et al (2002) Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother 36:75–77 Bergner R, Peters L, Schmitt V et al (2013) Leflunomide in dialysis patients with rheumatoid arthritis – a pharmacokinetic study. Clin Rheumatol 32:267–270 Russo PA, Wiese MD, Smith MD et al (2013) Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. Ann Pharmacother 47:e15 Inami Y, Yamaji K, Sato M et al (2013) Effects of dialysis on the pharmacokinetics of salazosulfapyridine. Rheumatol Int 33:535–539 Akiyama Y, Sakurai Y, Kato Y et al (2014) Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis. Mod Rheumatol 24:285–290 Schusziarra V, Ziekursch V, Schlamp R et al (1976) Pharmacokinetics of azathioprine under haemodialysis. Int J Clin Pharmacol Biopharm 14:298–302 Hest RM van, Gelder T van, Vulto AG et al (2009) Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 48:463–476 Mohammadpur AH, Nazemian F, Abtahi B et al (2008) Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant. Exp Clin Transplant 6:276–281 Winter BC de, Gelder T van, Mathot RA et al (2009) Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 31:585–591 Haubitz M, Groot K de (2008) Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 57:421–424 Haubitz M, Bohnenstengel F, Brunkhorst R et al (2002) Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495–1501 Meibohm B, Zhou H (2012) Renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol 52:54S–62S Kim DC, Reitz B, Carmichael DF et al (1995) Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. J Pharm Sci 84:575–580 Yang BB, Baughman S, Sullivan JT (2003) Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 74:85–94 Stankovic Stojanovic K, Delmas Y, Torres PU et al (2012) Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 27:1898–1901 Don BR, Spin G, Nestorov I et al (2005) The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 57:1407–1413 Senel S, Kisacik B, Ugan Y et al (2011) The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 30:1369–1372 Singh R, Cuchacovich R, Huang W, Espinoza LR et al (2002) Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol 29:636–637 Hammoudeh M (2006) Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford) 45:357–359 Marocchi E, Spadaro A, Giannakakis K et al (2010) Infliximab in a patient with ankylosing spondylitis and secondary IgA nephropathy requiring haemodialysis. Clin Exp Rheumatol 28:440 Saougou I, Papagoras C, Markatseli TE et al (2010) A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review. Clin Rheumatol 29:1455–1459 Kume K, Yamasaki M, Yoshikawa I et al (2011) Infliximab treatment in a patient with Crohn’s disease on haemodialysis. Colorectal Dis 13:341 Chiba M, Tsuda S, Tsuji T et al (2014) Crohn’s disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature. Medicine (Baltimore) 93:e54 Kleinert J, Lorenz M, Köstler W et al (2004) Refractory Wegener’s granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr 116:334–338 Yee AM, Pochapin MB (2001) Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 135:27–31 Sumida K, Ubara Y, Suwabe T (2013) Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res (Hoboken) 65:471–475 Laurino S, Chaudhry A, Booth A et al (2010) Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 25:3307–3314 Jillella AP, Dainer PM, Kallab AM et al (2002) Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. Am J Hematol 71:219–222 Nadri QJ (2009) Rituximab to treat active SLE in a hemodialysis patient. Saudi J Kidney Dis Transpl 20:1085–1086 Condon MB, Ashby D, Pepper RJ et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72:1280–1286 Iwamoto M, Honma S, Asano Y et al (2011) Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis. Rheumatol Int 31:559–560 Cañas-Ventura A, Rodríguez E, Andreu M et al (2013) Tocilizumab in amyloidosis-associated kidney disease secondary to inflammatory bowel diseases. Dig Dis Sci 58:2736–2737 Okuda Y, Ohnishi M, Matoba K et al (2014) Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 24:137–143 Mori S, Yoshitama T, Hidaka T et al (2015) Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study). Ann Rheum Dis (Epub ahead of print). doi:10.1136/annrheumdis-2014-206695 Bannwarth B, Kostine M, Poursac N (2013) A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 9:753–761 Krishnaswami S, Chow V, Boy M et al (2014) Pharmacokinetics of tofacitinib, a Janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol 54:46–52 Schipper LG, Fleuren HW, Bergh JP van den et al (2015) Treatment of osteoporosis in renal insufficiency. Clin Rheumatol (Epub ahead of print) Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130 Boonen S, Sellmeyer DE, Lippuner K et al (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74:641–648 Bergner R, Henrich D, Hoffmann M et al (2008) Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol 21:510–516 Meys E, Devogelaer JP, Geubel A et al (1992) Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity. J Rheumatol 19:807–809 Bir K, Herzenberg AM, Carette S (2006) Azathioprine induced acute interstitial nephritis as the cause of rapidly progressive renal failure in a patient with Wegener’s granulomatosis. J Rheumatol 33:185–187 Karstila KL, Rantalaiho VM, Mustonen JT et al (2010) Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. Clin Exp Rheumatol 28:73–78 Patel H, Barr A, Jeejeebhoy KN (2009) Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 23:170–176 Gremese E, Ferraccioli GF (2004) Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol 22(Suppl 35):S101–S107 Swarup A, Sachdeva N, Schumacher HR (2004) Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol 10:190–204 Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation) (2006) Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73:710–713 Kaneko K, Nanki T, Hosoya T et al (2010) Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol 20:632–636 Sacquépée M, Rouleau V, Cantin JF et al (2010) Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis. Nephrol Ther 6:537–540 Michel M, Henri P, Vincent FB et al (2013) Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine 80:660–663 Hirschberg R (2012) Renal complications from bisphosphonate treatment. Curr Opin Support Palliat Care 6:342–347